{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:30:55Z","timestamp":1759447855682},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,3,21]],"date-time":"2012-03-21T00:00:00Z","timestamp":1332288000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2318-12-11","type":"journal-article","created":{"date-parts":[[2012,3,22]],"date-time":"2012-03-22T23:41:59Z","timestamp":1332459719000},"source":"Crossref","is-referenced-by-count":30,"title":["The efficacy and safety of febuxostat for urate lowering in gout patients \u226565 years of age"],"prefix":"10.1186","volume":"12","author":[{"given":"Robert L","family":"Jackson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia A","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,21]]},"reference":[{"key":"747_CR1","first-page":"498","volume":"35","author":"E Krishnan","year":"2008","unstructured":"Krishnan E, Lienesch D, Kwoh CK: Gout in ambulatory care settings in the United States. J Rheumatol. 2008, 35: 498-501.","journal-title":"J Rheumatol"},{"key":"747_CR2","volume-title":"Health, United States, 2009: With special feature on medical technology","author":"National Center for Health Statistics","year":"2010","unstructured":"National Center for Health Statistics: Health, United States, 2009: With special feature on medical technology. 2010, Hyattsville: Centers for Disease Control. U.S. Department of Health and Human Services"},{"key":"747_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/1529-0131(195906)2:3<193::AID-ART1780020302>3.0.CO;2-8","volume":"2","author":"EC Bartels","year":"1959","unstructured":"Bartels EC, Matossian GS: Gout: six-year follow-up on probenecid (benemid) therapy. Arthritis Rheum. 1959, 2: 193-202. 10.1002\/1529-0131(195906)2:3<193::AID-ART1780020302>3.0.CO;2-8.","journal-title":"Arthritis Rheum"},{"key":"747_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.semnephrol.2004.10.001","volume":"25","author":"DH Kang","year":"2005","unstructured":"Kang DH, Nakagawa T: Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol. 2005, 25: 43-49. 10.1016\/j.semnephrol.2004.10.001.","journal-title":"Semin Nephrol"},{"key":"747_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ: Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984, 76: 47-56.","journal-title":"Am J Med"},{"key":"747_CR6","first-page":"1646","volume":"33","author":"N Dalbeth","year":"2006","unstructured":"Dalbeth N, Kumar S, Stamp L, Gow P: Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006, 33: 1646-1650.","journal-title":"J Rheumatol"},{"key":"747_CR7","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","volume":"76","author":"Y Takano","year":"2005","unstructured":"Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA: Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase. Life Sci. 2005, 76: 1835-1847. 10.1016\/j.lfs.2004.10.031.","journal-title":"Life Sci"},{"key":"747_CR8","unstructured":"Uloric\u00ae Full Prescribing Information. 2011, Deerfield, IL: Takeda Pharmaceuticals North America, Inc."},{"key":"747_CR9","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1081\/NCN-200027372","volume":"23","author":"MA Becker","year":"2004","unstructured":"Becker MA, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B, MacDonald P, Joseph-Ridge N: Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids. 2004, 23: 1111-1116. 10.1081\/NCN-200027372.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"747_CR10","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1177\/0091270008322035","volume":"48","author":"R Khosravan","year":"2008","unstructured":"Khosravan R, Kukulka MJ, Wu JT, Joseph-Ridge N, Vernillet L: The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2008, 48: 1014-1024. 10.1177\/0091270008322035.","journal-title":"J Clin Pharmacol"},{"key":"747_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/0091270005282634","volume":"46","author":"R Khosravan","year":"2006","unstructured":"Khosravan R, Grabowski BA, Mayer MD, Wu JT, Joseph-Ridge N, Vernillet L: The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2006, 46: 88-102. 10.1177\/0091270005282634.","journal-title":"J Clin Pharmacol"},{"key":"747_CR12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1081\/NCN-200027377","volume":"23","author":"S Hoshide","year":"2004","unstructured":"Hoshide S, Takahashi Y, Ishikawa T, Kubo J, Tsuchimoto M, Komoriya K, Ohno I, Hosoya T: PK\/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids. 2004, 23: 1117-1118. 10.1081\/NCN-200027377.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"747_CR13","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, Wells AF, Macdonald P, Lloyd E, Lademacher C: The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010, 12: R63-10.1186\/ar2978.","journal-title":"Arthritis Res Ther"},{"key":"747_CR14","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"SL Wallace","year":"1977","unstructured":"Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF: Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977, 20: 895-900. 10.1002\/art.1780200320.","journal-title":"Arthritis Rheum"},{"key":"747_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron. 1976, 16: 31-41. 10.1159\/000180580.","journal-title":"Nephron"},{"key":"747_CR16","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1097\/00003246-199310000-00016","volume":"21","author":"S Robert","year":"1993","unstructured":"Robert S, Zarowitz BJ, Peterson EL, Dumler F: Predictability of creatinine clearance estimates in critically ill patients. Crit Care Med. 1993, 21: 1487-1495. 10.1097\/00003246-199310000-00016.","journal-title":"Crit Care Med"},{"key":"747_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/15257770802136032","volume":"27","author":"MA Becker","year":"2008","unstructured":"Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N: Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008, 27: 585-591. 10.1080\/15257770802136032.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"747_CR18","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","volume":"32","author":"RL Wortmann","year":"2010","unstructured":"Wortmann RL, Macdonald PA, Hunt B, Jackson RL: Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010, 32: 2386-2397. 10.1016\/j.clinthera.2011.01.008.","journal-title":"Clin Ther"},{"key":"747_CR19","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.0105-2896.2009.00860.x","volume":"233","author":"F Martinon","year":"2010","unstructured":"Martinon F: Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev. 2010, 233: 218-232. 10.1111\/j.0105-2896.2009.00860.x.","journal-title":"Immunol Rev"},{"key":"747_CR20","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C: Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009, 36: 1273-1282. 10.3899\/jrheum.080814.","journal-title":"J Rheumatol"},{"key":"747_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","volume":"48","author":"HR Schumacher Jr","year":"2009","unstructured":"Schumacher HR, Becker MA, Lloyd E, MacDonald PA, Lademacher C: Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009, 48: 188-194.","journal-title":"Rheumatology (Oxford)"},{"key":"747_CR22","first-page":"2403","volume":"29","author":"E Arromdee","year":"2002","unstructured":"Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE: Epidemiology of gout: is the incidence rising?. J Rheumatol. 2002, 29: 2403-2406.","journal-title":"J Rheumatol"},{"key":"747_CR23","first-page":"1582","volume":"31","author":"KL Wallace","year":"2004","unstructured":"Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R: Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004, 31: 1582-1587.","journal-title":"J Rheumatol"},{"key":"747_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.23176","volume":"58","author":"RC Lawrence","year":"2008","unstructured":"Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008, 58: 26-35. 10.1002\/art.23176.","journal-title":"Arthritis Rheum"},{"key":"747_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/art.20405","volume":"51","author":"A Shoji","year":"2004","unstructured":"Shoji A, Yamanaka H, Kamatani N: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004, 51: 321-325. 10.1002\/art.20405.","journal-title":"Arthritis Rheum"},{"key":"747_CR26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/art.10511","volume":"47","author":"F Perez-Ruiz","year":"2002","unstructured":"Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A: Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002, 47: 356-360. 10.1002\/art.10511.","journal-title":"Arthritis Rheum"},{"key":"747_CR27","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/art.23007","volume":"57","author":"F Perez-Ruiz","year":"2007","unstructured":"Perez-Ruiz F, Liote F: Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?. Arthritis Rheum. 2007, 57: 1324-1328. 10.1002\/art.23007.","journal-title":"Arthritis Rheum"},{"key":"747_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/RHU.0b013e318204aab4","volume":"17","author":"A Whelton","year":"2011","unstructured":"Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L: Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011, 17: 7-13.","journal-title":"J Clin Rheumatol"},{"key":"747_CR29","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1093\/rheumatology\/ken305","volume":"47","author":"HK Choi","year":"2008","unstructured":"Choi HK, De Vera MA, Krishnan E: Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford). 2008, 47: 1567-1570. 10.1093\/rheumatology\/ken305.","journal-title":"Rheumatology (Oxford)"},{"key":"747_CR30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2337\/dc07-1276","volume":"31","author":"A Dehghan","year":"2008","unstructured":"Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC: High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008, 31: 361-362.","journal-title":"Diabetes Care"},{"key":"747_CR31","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","volume":"116","author":"HK Choi","year":"2007","unstructured":"Choi HK, Curhan G: Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007, 116: 894-900. 10.1161\/CIRCULATIONAHA.107.703389.","journal-title":"Circulation"},{"key":"747_CR32","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard.2009.122770","volume":"69","author":"MA De Vera","year":"2010","unstructured":"De Vera MA, Rahman MM, Bhole V, Kopec JA, Choi HK: Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis. 2010, 69: 1162-1164. 10.1136\/ard.2009.122770.","journal-title":"Ann Rheum Dis"},{"key":"747_CR33","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1002\/art.22014","volume":"54","author":"E Krishnan","year":"2006","unstructured":"Krishnan E, Baker JF, Furst DE, Schumacher HR: Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006, 54: 2688-2696. 10.1002\/art.22014.","journal-title":"Arthritis Rheum"},{"key":"747_CR34","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1001\/archinte.168.10.1104","volume":"168","author":"E Krishnan","year":"2008","unstructured":"Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH: Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008, 168: 1104-1110. 10.1001\/archinte.168.10.1104.","journal-title":"Arch Intern Med"},{"key":"747_CR35","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1093\/rheumatology\/keq037","volume":"49","author":"E Krishnan","year":"2010","unstructured":"Krishnan E: Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology (Oxford). 2010, 49: 1229-1238. 10.1093\/rheumatology\/keq037.","journal-title":"Rheumatology (Oxford)"},{"key":"747_CR36","doi-asserted-by":"publisher","first-page":"822","DOI":"10.3899\/jrheum.080768","volume":"36","author":"JG Hanly","year":"2009","unstructured":"Hanly JG, Skedgel C, Sketris I, Cooke C, Linehan T, Thompson K, van Zanten SV: Gout in the elderly-a population health study. J Rheumatol. 2009, 36: 822-830. 10.3899\/jrheum.080768.","journal-title":"J Rheumatol"},{"key":"747_CR37","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","volume":"124","author":"RT Keenan","year":"2011","unstructured":"Keenan RT, O'Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, Krasnokutsky S, Oh C, Pillinger MH: Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011, 124: 155-163. 10.1016\/j.amjmed.2010.09.012.","journal-title":"Am J Med"},{"key":"747_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C","volume":"43","author":"D Caspi","year":"2000","unstructured":"Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R: The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000, 43: 103-108. 10.1002\/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C.","journal-title":"Arthritis Rheum"},{"key":"747_CR39","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1023\/B:CARD.0000015855.02485.e3","volume":"17","author":"AJ Reyes","year":"2003","unstructured":"Reyes AJ: Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther. 2003, 17: 397-414.","journal-title":"Cardiovasc Drugs Ther"},{"key":"747_CR40","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S0895-4356(97)00101-7","volume":"50","author":"JH Gurwitz","year":"1997","unstructured":"Gurwitz JH, Kalish SC, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J: Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol. 1997, 50: 953-959. 10.1016\/S0895-4356(97)00101-7.","journal-title":"J Clin Epidemiol"},{"key":"747_CR41","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1592\/phco.28.4.437","volume":"28","author":"BA Briesacher","year":"2008","unstructured":"Briesacher BA, Andrade SE, Fouayzi H, Chan KA: Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008, 28: 437-443. 10.1592\/phco.28.4.437.","journal-title":"Pharmacotherapy"},{"key":"747_CR42","first-page":"164","volume":"14","author":"EQ Wu","year":"2008","unstructured":"Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, Krishnan E: Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm. 2008, 14: 164-175.","journal-title":"J Manag Care Pharm"},{"key":"747_CR43","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3899\/jrheum.080487","volume":"36","author":"EQ Wu","year":"2009","unstructured":"Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E: Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?. J Rheumatol. 2009, 36: 1032-1040. 10.3899\/jrheum.080487.","journal-title":"J Rheumatol"},{"key":"747_CR44","doi-asserted-by":"publisher","first-page":"925","DOI":"10.4065\/81.7.925","volume":"81","author":"CA Sarawate","year":"2006","unstructured":"Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW: Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006, 81: 925-934. 10.4065\/81.7.925.","journal-title":"Mayo Clin Proc"},{"key":"747_CR45","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/ard.2007.076182","volume":"67","author":"DH Solomon","year":"2008","unstructured":"Solomon DH, Avorn J, Levin R, Brookhart MA: Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008, 67: 609-613.","journal-title":"Ann Rheum Dis"},{"key":"747_CR46","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006, 65: 1312-1324. 10.1136\/ard.2006.055269.","journal-title":"Ann Rheum Dis"},{"key":"747_CR47","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1136\/ard.2008.091462","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, Brouwers JR: A randomised controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300-600 mg\/day versus benzbromarone 100-200 mg\/day in patients with gout. Ann Rheum Dis. 2009, 68: 892-897. 10.1136\/ard.2008.091462.","journal-title":"Ann Rheum Dis"},{"key":"747_CR48","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/art.30119","volume":"63","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT: Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011, 63: 412-421. 10.1002\/art.30119.","journal-title":"Arthritis Rheum"},{"key":"747_CR49","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3949\/ccjm.77a.09080","volume":"77","author":"H El-Zawawy","year":"2010","unstructured":"El-Zawawy H, Mandell BF: Managing gout: how is it different in patients with chronic kidney disease?. Cleve Clin J Med. 2010, 77: 919-928. 10.3949\/ccjm.77a.09080.","journal-title":"Cleve Clin J Med"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2318-12-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2318-12-11\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2318-12-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T09:08:30Z","timestamp":1468055310000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/1471-2318-12-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,21]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["747"],"URL":"https:\/\/doi.org\/10.1186\/1471-2318-12-11","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,21]]},"article-number":"11"}}